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Abstract
Obesity is associated with muscle lipid accumulation. Experimental models suggest that inflammatory cytokines, low
mitochondrial oxidative capacity and paradoxically high insulin signaling activation favor this alteration. The gastric
orexigenic hormone acylated ghrelin (A-Ghr) has antiinflammatory effects in vitro and it lowers muscle triglycerides while
modulating mitochondrial oxidative capacity in lean rodents. We tested the hypothesis that A-Ghr treatment in high-fat
feeding results in a model of weight gain characterized by low muscle inflammation and triglycerides with high muscle
mitochondrial oxidative capacity. A-Ghr at a non-orexigenic dose (HFG: twice-daily 200-mg s.c.) or saline (HF) were
administered for 4 days to rats fed a high-fat diet for one month. Compared to lean control (C) HF had higher body weight
and plasma free fatty acids (FFA), and HFG partially prevented FFA elevation (P,0.05). HFG also had the lowest muscle
inflammation (nuclear NFkB, tissue TNF-alpha) with mitochondrial enzyme activities higher than C (P,0.05 vs C, P=NS vs
HF). Under these conditions HFG prevented the HF-associated muscle triglyceride accumulation (P,0.05). The above effects
were independent of changes in redox state (total-oxidized glutathione, glutathione peroxidase activity) and were not
associated with changes in phosphorylation of AKT and selected AKT targets. Ghrelin administration following high-fat
feeding results in a novel model of weight gain with low inflammation, high mitochondrial enzyme activities and
normalized triglycerides in skeletal muscle. These effects are independent of changes in tissue redox state and insulin
signaling, and they suggest a potential positive metabolic impact of ghrelin in fat-induced obesity.
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Introduction
Obesity may be characterized by lipid accumulation in skeletal
muscle, and this alteration likely contributes to long-term
metabolic complications [1]. Experimental models suggest that
inflammatory cytokines, changes in muscle mitochondrial function
and paradoxical enhancement of insulin signaling at the AKT
level contribute to increase tissue lipid deposition in the presence
of weight gain and high lipid availability [1–3]. Pro-oxidant
changes in redox state may further contribute to inflammation and
altered mitochondrial function, and they are commonly associated
with muscle lipid accumulation [4,5].
Ghrelin is a gastric hormone with orexigenic and adipogenic
effects that may favor weight and fat gain in vivo [6,7]. Acylated
ghrelin (A-Ghr) has been however reported to lower muscle
triglyceride content in healthy and uremic lean rodents,
associated with enhanced skeletal muscle mitochondrial oxidative
capacity [8,9]. Antiinflammatory and antioxidant effects of A-
Ghr have been also demonstrated in vitro [10–12]. The impact of
A-Ghr administration on muscle redox state, inflammatory
mediators, mitochondrial oxidative capacity and triglyceride
content following diet-induced weight gain remains however
undetermined.
In the current study we therefore administered A-Ghr for four
days at a non-orexigenic dose in a rodent model of high-fat diet-
inducedobesity. We hypothesizedthat A-Ghr administrationresults
in a model of weight gain characterized by low muscle oxidative
stress and inflammation, high muscle mitochondrial oxidative
capacity and low tissue triglycerides. The potential association
between muscle triglyceride changes and altered muscle insulin
signaling at the AKT level was also investigated, since AKT
activation under non-stimulated conditions has been paradoxically
reported to contribute to muscle lipid accumulation during high-fat
feeding [2], and tissue-specific insulin-sensitizing effects of ghrelin
have been shown in non-obese experimental models [13].
Results
Body weight, plasma metabolic profile (Table 1)
Initial body weight was comparable in the three experimental
groups, while final body weight and the weight of epidydimal and
retroperitoneal fat were higher in HF compared to control
animals. HFG had food intake and final body weight comparable
to HF. Weight gain during the four-day ghrelin treatment was
however moderately higher in HFG compared to HF animals,
although this alteration was not associated with higher caloric
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pads were also comparable in HF and HFG groups. Blood glucose
was higher while plasma insulin was similar in HF and control
animals. In HFG, both blood glucose and plasma insulin were
comparable to control and HF groups, while plasma free fatty
acids were markedly lower in HFG than in the HF group.
Muscle inflammation, mitochondrial enzyme activities
and triglycerides (Figure 1–2)
A-Ghr treatment lead to lower levels of nuclear p65 NFkB and
tissue TNF-alpha in skeletal muscle compared to both HF and C
(Figure 1a–b). Mitochondrial enzyme activities were conversely
higher in HFG than in control and HF animals, although this
difference only reached statistical significance between HFG and
control values (Figure 2a–b). Under the above conditions, ghrelin
treatment was associated with normalization of the high-fat diet-
induced skeletal muscle triglyceride accumulation (Figure 2c).
Plasma TBARS, muscle redox state and muscle
glutathione peroxidase activity (Figure 3)
HF had high plasma TBARS concentrations indicating high
systemic lipid peroxidation. Despite this alteration, skeletal muscle
redox state as reflected by the GSSG/GSH ratio was unchanged
in fat-fed animals. Glutathione peroxidase is a major antioxidant
enzyme and we tested the hypothesis that lack of changes in
muscle redox state is associated with a stimulation of its activity in
HF. A stimulation of glutathione peroxidase activity was indeed
observed in HF compared to control group. HFG had similar
plasma TBARS, muscle GSSG/GSH ratio and glutathione
peroxidase activity compared to the HF group.
Muscle AKT, GSK and FOXO1 phosphorylation (Figure 4)
HF had high AKT phosphorylation compared to control
animals, associated with higher phosphorylation of FOXO1 and
GSK, although the latter did not reach statistical significance.
A-Ghr had no independent impact on insulin signalling since
muscle AKT, GSK and FOXO1 phosphorylation levels in HFG
were comparable to HF, and higher than those observed in the
control group.
Discussion
The study demonstrated that acylated ghrelin administration
following high-fat diet-induced weight gain induces anti-inflam-
matory changes and prevents triglyceride accumulation in rat
skeletal muscle. These effects were associated with higher
mitochondrial enzyme activities compared to control animals,
and they were independent of changes in muscle redox state and of
insulin signaling activation. Peripheral acylated ghrelin adminis-
tration in fat-fed rats therefore results in a novel model of weight
gain characterized by low inflammation, high mitochondrial
enzyme activities and normal triglyceride content in skeletal
muscle. Under the above conditions, ghrelin also had no negative
impact on plasma metabolic profile but lead to a limitation of the
diet-induced increase of circulating free fatty acids.
Table 1. Initialbodyweight(BW),bodyweightattheendofthe
one-month dietary treatment (before start of ghrelin or saline
injection treatments), body weight changes before start of
ghrelin or saline treatments, body weight changes during 4-day
ghrelin or saline treatments, total 4-day caloric intake during 4-
day ghrelin or saline treatment, retroperitoneal and epidydimal
fatpadweights,plasmainsulin,glucoseandfreefattyacids(FFA)
concentrations in the three experimental groups.
Control HF HFG
Initial BW (g) 29567
a 29769
a 29469
a
BW 1-mo (g) 37867
a 412612
b 40868
b
BW changes 1-mo (g) 8468
a 11567
b 11264
b
BW changes 4-day (g) 861
a 962
a 1561.5
b
Caloric intake 4-day (cal) 505613
a 631611
b 639612
b
Fat – Retroperitoneal (g) 5.760.4
a 9.460.7
b 9.460.5
b
Fat – Epidydimal (g) 5.360.4
a 9.260.5
b 8.460.5
b
Insulin (ng/ml) 6.861.4
a 5.960.8
a 7.261
a
Glucose (mg/dl) 10763
a 11864
b 11463
ab
FFA (mmol/l) 0.2160.026
a 0.5960.062
b 0.3960.047
c
Data are Mean6SE. Different letters denote statistically significant differences:
P,0.05 by ANOVA and post-hoc tests.
doi:10.1371/journal.pone.0026224.t001
Figure 1. Acylated ghrelin during HF diet lowers gastrocnemius muscle proinflammatory molecules. Effects of one-month high-fat
feeding without (HF) or with (HFG) 4-day acylated ghrelin treatment on gastrocnemius muscle levels of nuclear p65 NFkB subunit (a) and TNF-alpha
protein (b). Different letters denote statistically significant differences (P,0.05 ANOVA and post-hoc test).
doi:10.1371/journal.pone.0026224.g001
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of metabolic abnormalities that characterize weight gain and fat
accumulation [1]. Acylated ghrelin treatment was reported to lower
gastrocnemiusmuscletriglycerides in lean and uremicrodents [8,9],
and the current data are consistent with the concept that ghrelin
prevents muscle lipid accumulation also in the presence of high
dietary fat availability. Ghrelin effects on muscle triglycerides are
clustered with enhanced tissue oxidative capacity compared to
control animals, although this effect was not statistically significant
whencomparedtohigh-fatfedanimalstreatedwithsaline.Effectsof
acylated ghrelin towards enhanced muscle mitochondrial enzyme
activities where previously demonstrated in lean and uremic
animals, and more pronounced enhancement of muscle oxidative
capacity could have potentially contributed to prevent triglyceride
accumulation also in the current model [8,9]. The current data also
provide the first demonstration of antiinflammatory effects of
ghrelin in skeletal muscle, consistent with previous reports in vitro
and in vivo at systemic level [10,12]. Since TNF-alpha may reduce
skeletal muscle mitochondrial citrate synthase activity in vivo [3],
low TNF-alpha could have contributed to ghrelin-induced
mitochondrial changes compared to control animals. In addition
to muscle changes, ghrelin had no negative impact on plasma
metabolicprofile interms of glucose and insulin concentrations,and
it limited the diet-induced increase in circulating free fatty acids.
Taken together, the current findings indicate potentially beneficial
muscle metabolic effects of sustained acylated ghrelin administra-
tion in fat-induced obesity. Notably, ghrelin effects were expectedly
independent of reductions in body weight, that was instead further
moderately increased during the four-day ghrelin administration.
The latter change is in agreement with previous findings by us and
others [7,8], indicating that ghrelin may enhance body weight
independently of enhanced food intake. This effect could theoret-
ically involve changes in physical activity, that were not investigated
under the current experimental design. Changes in body weight
could have alsoatleastinpart involvedghrelineffects toenhancefat
deposition in adipose tissue by stimulation of lipogenesis and
potential inhibition of lipolysis [14,15].
In the current study, one-month high-fat feeding was associated
with enhanced rather than impaired phosphorylation of muscle
AKT and further downstream steps of insulin signaling in the
absence of acute insulin stimulation. This finding is in agreement
with emerging evidence that insulin signaling activation under
non-stimulated conditions characterizes relatively early stages of
diet-induced obesity [2], and could favor the onset of obesity-
associated metabolic complications [2]. Under the current
experimental conditions, acylated ghrelin had no independent
effects on AKT, GSK and FOXO1 phosphorylation compared to
high-fat feeding per se. We recently demonstrated that acylated
ghrelin treatment normalizes impaired AKT phosphorylation in
gastrocnemius muscle in a rodent model of chronic kidney disease
Figure 2. Acylated ghrelin with HF diet enhance gastrocnemius muscle mitochondrial enzyme activities. Effects of one-month high-fat
feeding without (HF) or with (HFG) 4-day acylated ghrelin treatment ongastrocnemiusmuscle activities of mitochondrial cytochrome c oxidase (COX) (a)and
ci t r a t es y n t h a s e( C S )( b )a n do nm u s c l et r i g l yc e r i d ec o n t e n t( c ) .D ifferent letters denote statistically significant differences (P,0.05 ANOVA and post-hoc test).
doi:10.1371/journal.pone.0026224.g002
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normalization of food intake in anorectic animals [9]. On the
other hand, insulin-sensitizing effects of ghrelin did not occur in
gastrocnemius muscle in lean rodents [13] and this finding is
consistent with the current observations in diet-induced obesity.
Fat feeding per se did not modify muscle inflammation or
mitochondrial enzyme activities, but the inability to lower tissue
proinflammatory cytokines and to further enhance mitochondrial
oxidative capacity likely contributed to muscle triglyceride accu-
mulation in untreated fat-fed animals. Previous studies suggest that
the reported effects of high-fat feeding on muscle inflammation and
mitochondrial oxidative capacity are at least in part dependent on
treatment duration. More prolonged treatments may result in
higher inflammation and lower mitochondrial function, associated
with the onset of oxidative stress [3,16], while our findings agree
with studies of comparable duration [17] in suggesting that adaptive
mechanisms may limit fat-induced skeletal muscle alterations in
early stages of dietary treatment. Enhanced glutathione peroxidase
activity was indeed associated with high-fat feeding in the current
model in agreement with previous reports [18], and it could have
contributed to prevent changes in muscle redox state, inflammation
and mitochondrial enzyme activities [4,5]. Activation of muscle
antioxidant defenses by fat feedingcould have also masked potential
independent antioxidant effects of acylated ghrelin, since such
effects have been reported to involve glutathione availability in vitro
[11,12]. Also based on the above observations, the positive effects of
ghrelin in the current model provide a strong rationale to further
assess the impact of ghrelin administration in obesity models with
different degrees of muscle metabolic abnormalities.
In conclusion, acylated ghrelin administration during high-fat
feedingresultsinanovelmodelofweightgainwithlowinflammation
and lower triglycerides in rat skeletal muscle, associated with high
mitochondrial oxidative capacity compared to control animals.
These effects are independent of changes in tissue redox state and
insulin signaling, and they suggest a potential positive metabolic
impact of acylated ghrelin in high-fat diet-induced weight gain.
Materials and Methods
Animals and experimental protocol
The experimental protocol was approved by the Committee for
Animal Studies at Trieste University. Animals were housed in
individual cages, and care was taken to minimize stress during all
procedures, that did not involve invasive treatments and
techniques. At the time of sacrifice adequate anaesthesia was
achieved before any procedures were performed, as described
below. Thirty 12-week-old male Wistar rats were purchased from
Harlan-Italy (San Pietro al Natisone, Udine, Italy) and kept for
two weeks in the Animal Facility of the University of Trieste in
individual cages on a 12-h light/12-h dark cycle (0600 h/1800 h).
Animals were then randomly assigned to undergo a high-fat
feeding program for one month with a diet containing 60% energy
from fat (HF, n=20; diet composition: Protein 17%, Fat 34%,
Carbohydrate approximately 45% with Fiber 5%) or a control diet
containing 10% energy from fat (C, n=10; Protein 23%, Fat 5%,
Carbohydrate approximately 65% with Fiber 5%). Both diets were
purchased from Mucedola, Settimo Milanese, MI, Italy. All
animals were weighed and food intake was monitored two times
per week. After thirty days, animals in the HF group were
randomized to receive eight subcutaneous injections of either
acylated rat ghrelin as previously reported [8,13] (AnaSpec, San
Jose, CA) (HFG, 200 mg ghrelin/injection) or saline, that was also
administered to control rats. Injections were administered two
times per day at 8 PM and 8 AM, beginning in the evening of day
Figure 3. Acylated ghrelin effects are independent of changes in gastrocnemius muscle redox state. Effects of one-month high-fat
feeding without (HF) or with (HFG) 4-day acylated ghrelin treatment on plasma TBARS concentration (a) and on gastrocnemius muscle glutathione
peroxidase activity (b), and total 1 oxidized glutathione ratio (c). Different letters denote statistically significant differences (P,0.05 ANOVA and post-
hoc test).
doi:10.1371/journal.pone.0026224.g003
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After the last injection, food was withdrawn for three hours before
the intraperitoneal injection of an overdose of sodium pentobar-
bital (80 mg/kg). After achievement of adequate anaesthesia,
gastrocnemius muscle was dissected and quickly frozen in liquid
nitrogen to be stored at 280 before analyses. The epidydimal and
retroperitoneal fat pads were then dissected and weighed, and
blood was finally collected through cardiac puncture for plasma
separation and storage at 280.
Protein analysis
Total tissue protein was extracted from homogenized tissue as
described [8,13]. Nuclear protein extracts were obtained as
follows: 100 mg tissue were homogenized in lysis buffer (10 mM
HEPES pH 7,9, 10 mM KCl, 1,5 mM MgCl2, 1 mM DTT,
0,5 mM PMSF) containing protease inhibitors, followed by
addition of 1% Nonidet P-40. The homogenate was incubated
on ice for 20 min and then centrifuged at 12500 rpm 4uC for
30 seconds. Pellets were resuspended in 100 ml extraction buffer
(20 mM HEPES pH 7,9, 420 mM NaCl, 1,5 mM MgCl2,
0,2 mM EDTA, 5% Glycerol, 1 mM DTT, 0,5 mM PMSF)
added with protease inhibitors and the tube was gently rocked on
ice for 30 min. The mixture was then spun at 12500 rpm at 4uC
for 15 min and the resulting supernatant containing nuclear
proteins was stored at 280 C until analyses. Protein concentration
in all samples was measured by spectrophotometer (BCA Protein
Assay Reagent, Pierce, Rockford, IL, USA). For measurement of
tissue p65 NFkB subunit (TransAM, Active Motif North America,
Carlsbad, CA, USA) and TNF-alpha (Pierce Biotechnology,
Rockford, IL, USA) nuclear and total tissue proteins respectively
and commercially available kits were used. Total tissue proteins
and commercially available antibodies (Cell Signaling Technology,
Danvers, Ma, USA) were also used to measure phosphorylated
and total protein levels of AKT and its downstream targets
glycogen synthase kinase (GSK) and FOXO1 by immunoblotting.
Cytochrome c oxidase (COX) and citrate synthase (CS)
activity
COX and CS enzyme activities were measured spectrophoto-
metrically from tissue homogenates as referenced [8].
Muscle total and oxidized glutathione, glutathione
peroxidase activity
Glutathione is the major antioxidant system in skeletal muscle
and tissue total and oxidized glutathione were therefore deter-
mined as indicators of redox state. Muscle total and oxidized
Figure 4. Acylated ghrelin during HF diet does not alter AKT-dependent gastrocnemius insulin signaling. Effects of one-month high-fat
feeding without (HF) or with (HFG) 4-day acylated ghrelin treatment on gastrocnemius muscle phosphorylation of AKT (a), glycogen synthase kinase
(GSK) (b) and FOXO1 (c). Different letters denote statistically significant differences (P,0.05 ANOVA and post-hoc test).
doi:10.1371/journal.pone.0026224.g004
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(Trevigen, Gaithersburg, MD, USA) according to manufacturer’s
instructions. Briefly, ,50 mg of gastrocnemius sample were
cleaned from blood and fibrous residues and homogenized in ice
cold 5% (w/v) metaphosphoric acid (20 ml/g tissue). Homoge-
nates were then centrifuged (12.0006g for 159) and the
supernatant was used for total glutathione measurement after
appropriate dilution. For oxidized glutathione, samples were
pretreated with 2 M 4-vinylpyridine. Reduced glutathione was
calculated by subtracting the oxidized fraction from the total. To
further determine potential diet- and ghrelin-induced muscle
changes in enzyme activity of the antioxidant scavenging enzyme
glutathione peroxidase, the latter was also determined by
spectrophotometry and a commercially available kit following
the manufacturer’s instructions (HT Glutathione Peroxidase Assay
Kit, Trevigen, Gaithersburg, MD, USA).
Plasma metabolic profile
Plasma insulin concentration was measured by ELISA using a
commercially available kit (Insulin Rat/Mouse ELISA, DRG
Diagnostics, Marburg, Germany Marburg). Plasma FFA were
determined spectrophotometrically using an acyl-CoA oxidase-
based colorimetric kit (NEFA-C, WAKO Pure Chemical Indus-
tries). Plasma thiobarbituric acid-reactive substance (TBARS) were
measured spectrophotometrically using commercial kit (TBARS
assay kit, OXItek Zeptometrix Corporation).
Statistical analysis
Results in the three groups were compared using One-Way
ANOVA. Post-hoc tests were then used to compare results
between two groups. P values,0.05 were considered statistically
significant.
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